Clinical Pharmacology Unit, GlaxoSmithKline, Addenbrooke's Hospital, Cambridge CB2 2GG, UK.
Medicines Research Centre, GlaxoSmithKline, Via Fleming 4, 37134 Verona, Italy.
J Affect Disord. 2013 Nov;151(2):667-672. doi: 10.1016/j.jad.2013.07.015. Epub 2013 Jul 31.
Changes in circulatory aminopeptidases [dipeptidyl-peptidase-IV (DPP-IV), Prolyl-oligopeptidase (POP) and Leucine aminopeptidase (LAP)] activities have been found to be associated with psychiatric illnesses and inflammatory diseases.
The discriminatory indices of aminopeptidases activities were assessed by enzymatic assays in plasma samples from 240 unipolar depression (UD) patients and 264 matched controls. In addition the relationship between soluble and cellular DPP-IV activity was determined in plasma and blood cells from healthy subjects.
Greater than 95% of the plasma DPP-IV activity could be blocked by inhibitors, demonstrating the specificity of the assay. Also, DPP-IV protein and activity levels were strongly correlated. In contrast, only 50% of the membrane-bound activity in blood cells was inhibited, which suggested that other similar peptidases may be present in these cells. UD patients had decreased plasma levels of DPP-IV and POP activities compared to healthy controls with a concomitant increase in LAP activity. Finally, testing of the LAP/DPP-IV ratio resulted in good discrimination of UD patients from controls with an area under the curve-receiver operating characteristic of 0.70.
Further biological validation studies using different cohorts are warranted.
The finding that plasma DPP-IV activity was decreased and LAP activity was increased in UD patients suggests the potential value for testing the levels of these enzymes for improved classification of patients. In addition, the changes in these enzymes, suggests that the proteolytic maturation of their proneuropeptide and prohormone subtrates may also be affected in UD, resulting in altered production of the associated bioactive peptides.
循环氨基肽酶(二肽基肽酶-IV [DPP-IV]、脯氨酰寡肽酶 [POP] 和亮氨酸氨基肽酶 [LAP])活性的变化已被发现与精神疾病和炎症性疾病有关。
通过酶促测定法评估了来自 240 名单相抑郁(UD)患者和 264 名匹配对照者的血浆样本中氨基肽酶活性的鉴别指数。此外,还在健康受试者的血浆和血细胞中确定了可溶性和细胞 DPP-IV 活性之间的关系。
大于 95%的血浆 DPP-IV 活性可被抑制剂阻断,表明测定具有特异性。此外,DPP-IV 蛋白和活性水平高度相关。相比之下,只有 50%的血细胞中的膜结合活性被抑制,这表明这些细胞中可能存在其他类似的肽酶。与健康对照组相比,UD 患者的血浆 DPP-IV 和 POP 活性降低,同时 LAP 活性升高。最后,对 LAP/DPP-IV 比值的检测可使 UD 患者与对照组得到很好的区分,曲线下面积-接收者操作特征为 0.70。
需要使用不同队列进行进一步的生物学验证研究。
UD 患者血浆 DPP-IV 活性降低和 LAP 活性升高的发现表明,测试这些酶的水平可能对改善患者分类具有潜在价值。此外,这些酶的变化表明其前神经肽和前激素底物的蛋白水解成熟也可能受到影响,导致相关生物活性肽的产生发生改变。